Administration of PL1-CD137 + anti-CD137 Ab dramatically decreased the tumor growth rate by 5-fold (18 days after inoculation) (Supplementary Fig. 8a, b), and increased the overall survival time compared to PBS and PL1 (empty nanoparticle) + anti-CD137 Ab (Supplementary Fig. 8c). This evidence concerns the gene TNFRSF9 and neoplasm.